Almost 20 million people are diagnosed with cancer globally each year, and it remains a leading cause of mortality worldwide. Significant disparities are observed in countries with high Human Development Indexes, such as the UK and the US. A deeper understanding of how various factors contribute to both cancer risk and treatment can improve precision prevention and precision medicine outcomes, while also promoting cancer health equity. This project takes a comprehensive cancer center program approach to integrate multi-level (biological, behavioral, environmental, and social) and multi-omic (genomic, proteomic, and metabolomic) data analyses aimed at unraveling the complex interplay between determinants of health (DOH) that influence the cancer control continuum (etiology, prevention, detection, diagnosis, treatment, and survivorship). Our vision is to leverage our 36 program members’ subject matter expertise in biological (n=16), behavioral (n=12), environmental (n=4), and social (n=4) DOH, as well as -omic, biostatistics, and bioinformatic analyses (n=2), to design and deliver multi-level intervention projects focused on primordial, primary, secondary, and tertiary prevention. Our goals are to:
1. Identify novel biological, behavioral, environmental, and social DOH predictors for comprehensive cancer prevention and control.
2. Explore new susceptibility/risk, diagnostic, monitoring, prognostic, predictive, pharmacodynamic/response, and safety biomarkers for common and rare cancers.
3. Assess the combined effects of multi-level and multi-omic data on developing and dying from common and rare cancers, aiming to uncover new preventive measures and therapeutic targets.